| Literature DB >> 30134818 |
Hélène Cabanas1,2, Katsuhiko Muraki3, Natalie Eaton4,5, Cassandra Balinas4,5, Donald Staines4,5, Sonya Marshall-Gradisnik4,5.
Abstract
BACKGROUND: Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME) is a debilitating disorder that is accompanied by reduced cytotoxic activity in natural killer (NK) cells. NK cells are an essential innate immune cell, responsible for recognising and inducing apoptosis of tumour and virus infected cells. Calcium is an essential component in mediating this cellular function. Transient Receptor Potential Melastatin 3 (TRPM3) cation channels have an important regulatory role in mediating calcium influx to help maintain cellular homeostasis. Several single nucleotide polymorphisms have been reported in TRPM3 genes from isolated peripheral blood mononuclear cells, NK and B cells in patients with CFS/ME and have been proposed to correlate with illness presentation. Moreover, a significant reduction in both TRPM3 surface expression and intracellular calcium mobilisation in NK cells has been found in CFS/ME patients compared with healthy controls. Despite the functional importance of TRPM3, little is known about the ion channel function in NK cells and the epiphenomenon of CFS/ME. The objective of the present study was to characterise the TRPM3 ion channel function in NK cells from CFS/ME patients in comparison with healthy controls using whole cell patch-clamp techniques.Entities:
Keywords: Calcium; Chronic fatigue syndrome/Myalgic encephalomyelitis; Flow cytometry; Natural killer cells; Patch-clamp; Transient receptor potential Melastatin 3
Mesh:
Substances:
Year: 2018 PMID: 30134818 PMCID: PMC6092868 DOI: 10.1186/s10020-018-0046-1
Source DB: PubMed Journal: Mol Med ISSN: 1076-1551 Impact factor: 6.354
Blood parameters and patient demographic
| CFS/ME | HC | ||
|---|---|---|---|
| Age (years) | 42.5 ± 6.05 | 42.8 ± 5.47 | 0.872 |
| Gender n(%) | |||
| Male | 2 (20%) | 2 (20%) | 1.000 |
| Female | 4 (80%) | 4 (80%) | |
| BMI (kg/m2) | 23.54 ± 0.54 | 23.35 ± 1.37 | 0.240 |
| SF-36 | |||
| Fatigue (%) | 30.42 ± 8.91 | 77.92 ± 6.25 |
|
| General Health (%) | 31.25 ± 5.97 | 74.31 ± 4.50 |
|
| Physical Functioning (%) | 70.83 ± 6.64 | 93.33 ± 4.77 |
|
| Role Physical (%) | 20.83 ± 9.64 | 87.50 ± 12.5 |
|
| Role Emotional (%) | 59.38 ± 9.24 | 96.88 ± 3.13 |
|
| Social Functioning (%) | 37.5 ± 5.59 | 95.83 ± 4.17 |
|
| Body Pain (%) | 49.17 ± 5.27 | 84.17 ± 8.41 |
|
| Pathology | |||
| White Cell Count (×109/L) | 5.58 ± 0.30 | 7.13 ± 0.49 |
|
| Lymphocytes (×109/L) | 1.99 ± 0.2 | 1.75 ± 0.22 | 0.423 |
| Neutrophils (× 109/L) | 3.03 ± 0.23 | 4.78 ± 0.42 |
|
| Monocytes (× 109/L) | 0.41 ± 0.05 | 0.39 ± 0.06 | 0.748 |
| Eosinophils (× 109/L) | 0.12 ± 0.02 | 0.18 ± 0.06 | 0.936 |
| Basophils (× 109/L) | 0.04 ± 0.01 | 0.04 ± 0.002 | 0.799 |
| Platelet (× 109/L) | 265.0 ± 23.36 | 266.17 ± 15.70 | 1.00 |
| Red Cell Count (× 1012/L) | 4.63 ± 0.09 | 4.69 ± 0.13 | 0.63 |
| Haematocrit | 0.41 ± 0.01 | 0.42 ± 0.01 | 0.624 |
| Haemoglobin (g/L) | 135.0 ± 3.52 | 139.67 ± 5.21 | 0.687 |
SF-36 scores were analysed using participant questionnaire responses. Results from routine full blood analysis in CFS/ME patients and HC. Data presented as mean ± SD. Abbreviations: CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; HC, healthy controls; BMI, body mass index
Fig. 1Natural Killer cell purity. Bar graphs representing isolated NK cell purity for HC and CFS/ME patients. Data presented as mean ± SEM. HC = 98.07% ± 0.80 and CFS/ME = 98.28% ± 0.58. Abbreviations: CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; HC, healthy controls; NK cell, natural killer cell
Fig. 3TRPM3 activity after ononetin modulation. Data were obtained under whole-cell patch clamp conditions. a. A representative time-series of current amplitude at + 100 mV and − 100 mV showing the effect of 10 μΜ ononetin on ionic currents in the presence of PregS in isolated NK cells from HC. b I–V before and after application of ononetin in a cell as shown in (a.). c A representative time-series of current amplitude at + 100 mV and − 100 mV showing the effect of 10 μΜ ononetin on ionic currents in the presence of PregS in isolated NK cells CFS/ME patients. d. I–V before and after application of ononetin in a cell as shown in (c.). e. f Scatter plots representing change of each current amplitude before and after ononetin application in all NK cells from HC and CFS/ME patients. Each cell represented as red lines had reduction in currents by ononetin. g Table summarizing data for sensitive and insensitive cells to 10 μΜ ononetin in HC (N = 6; n = 33) compared to CFS/ME patients (N = 6; n = 28). Data are analysed with Fisher’s exact test. Abbreviations: CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; HC, healthy controls
Fig. 2TRPM3 activity after PregS stimulation. Data were obtained under whole-cell patch clamp conditions. a A representative time-series of current amplitude at + 100 mV and − 100 mV showing the effect of 100 μΜ PregS on ionic currents in isolated NK cells from HC. b I–V before and after PregS stimulation in a cell corresponding with (a.). c A representative time-series of current amplitude at + 100 mV and − 100 mV showing the effect of 100 μΜ PregS on ionic currents in isolated NK cells from CFS/ME patients. d. I–V before and after PregS stimulation in a cell as shown in (c.). e Bar graphs representing TRPM3 current amplitude at + 100 mV after stimulation with 100 μΜ PregS in CFS/ME patients (N = 6; n = 33) compared with HC (N = 6; n = 29). Data are represented as mean ± SEM. Abbreviations: CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis; HC, healthy control; NK, natural killer